Two Sealed Airtight Medical Vials Against Bright Background Front View. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations.

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule ...

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...

NEW ORLEANS -- Off-label use of oral elagolix (Orilissa) may be a more patient-friendly alternative to standard-of-care injectable GnRH antagonists for ovulation suppression during in vitro ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

In 1977, the Nobel Prize in Physiology or Medicine was awarded to Roger Guillemin and Andrew Schally for their discovery and synthesis of gonadotropin-releasing hormone (GnRH), a key regulator of ...

Please provide your email address to receive an email when new articles are posted on . “Many transgender boys do not want to compromise their adult height,” Sabine E. Hannema, MD, PhD, a pediatric ...